Aquestive Therapeutics Releases Topline PK Data From Self-Administration Study Of Anaphylm; Meets Primary Endpoints With Comparable PK Whether Administered By Subjects Or HCPs; Final OAS Challenge Study Enrolling; Pre-NDA Meeting Anticipated By End Of Q3 2024
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care
- Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)
- Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling
- Continues to anticipate requesting a pre-New Drug Application (NDA) meeting before the end of the third quarter